COL18A1 and non-small cell lung carcinoma: Considering these promising data of the potential therapeutic benefits of rh‐endostatin plus camrelizumab, we retrospectively reviewed the efficacy and safety of rh‐endostatin combined with camrelizumab in patients with advanced‐stage NSCLC in a first‐line setting.